About International NASH Day
International NASH Day - June 12, 2019 - is dedicated to increasing awareness about non-alcoholic steatohepatitis, or NASH, among various populations: the general public, at-risk patients, the medical community, public health authorities, and the media.
Through locally-organized events around the world, advocates raise awareness and promote early intervention to treat fatty liver disease and its more advanced form, NASH, which affects more than 115 million people worldwide.
The first International NASH Day was held in 2018.
About the Global Liver Institute
The Global Liver Initiative (GLI) was founded in 2014 to improve the lives of individuals and families impacted by liver disease through promoting innovation, encouraging collaboration, and scaling optimal approaches to help eradicate liver diseases. GLI works so that liver health can take its proper place on the global public health agenda consistent with its prevalence and impact. GLI is the host of International NASH Day globally.
On International NASH Day 2019, a new policy report on non-alcoholic steatohepatitis (NASH) was launched by The Health Policy Partnership (HPP) in collaboration with a steering committee consisting of Ms. Donna R. Cryer, President & CEO of Global Liver Institute, Professor Quentin M. Anstee, Dr. Farhana Bin Lootah, Dr. Hannes Hagström, Dr. Jeffrey V. Lazarus, Professor Michael P. Manns, Professor Manuel Romero-Gómez, Professor Lawrence Serfaty and Professor Zobair M. Younossi.
The report aims to prompt a measured policy response to the anticipated rise of NASH in years to come. Focused on Europe and the Middle East, it offers up-to-date estimates of the epidemiology and impact of NASH, and highlights key strategic issues to improve clinical management and health system preparedness from a policy perspective. The report proposes five key recommendations for action for policymakers. The report has been initiated and funded by Gilead Sciences Europe. Gilead has had no input into the report content.
Follow @HealthPolicyPtp for more information.
How do people learn they have NASH? What effect has it had on their lives? How do patients feel and what is their outlook? Answers to these and other questions are being provided by NASH patients from around the world.
Editor’s Note: These are the exact words of the submitter. GLI has added words in parentheses, added punctuation where helpful and/or corrected typos or spelling errors.
Share your story
Social Media Guide
Tips for your social media campaign
Follow and share the content at
Use our hashtag, #NASHday!
Explore #NASHday and repost content from other International NASH Day participants
Share personal stories of NASH patients and their caregivers to help people understand the effects of NASH throughout many different populations
I join @globalliver in supporting International #NASHday and the fight against the epidemic of non-alcoholic steatohepatitis (NASH).
Celebrate International #NASHday by sharing your story!
Did you know? The #liver disease NASH affects 7-12% of adults worldwide. #NASHday
Did you know? The #liver disease NASH affects 12% of adults in the US. #NASHday
About 30 million Americans have the #liver disease NASH. #NASHday
The prevalence of NASH is expected to increase by 63% by 2030 in the US. #NASHday
12% of Americans have NASH, yet only 6% of at-risk Americans have ever heard of the disease. #NASHday
Many Hispanics in the US possess the PNPLA3 gene variation, which has been associated with a heightened risk of #NAFLD & #NASH. #NASHday #fattyliver
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in Western countries. #fattyliver #liverhealth #nash #NAFLD #NASHday
Non-alcoholic fatty liver disease (NAFLD) affects almost one in four people worldwide. #fattyliver #liverhealth #nash #NAFLD
The global prevalence of non-alcoholic fatty liver disease (NAFLD) is expected to increase to over 28% by 2030. #fattyliver #liverhealth #nash #NAFLD #NASHday
Most NASH patients show no #symptoms, and most people with NASH are not diagnosed. #NASHday
Up to 40% of NASH patients will progress to #cirrhosis, liver failure, and #hepatocellular carcinoma. #NASHday
Concurrent conditions are often seen in NASH patients: more than 70% are obese, up to 75% have type 2 diabetes, and anywhere from 20-80% have hyperlipidemia. #NASHday
NASH was the fastest growing reason for liver transplantation between 2002 and 2011 and is expected to be the number one cause of liver transplantation by 2020. #NASHday
Despite its prevalence, NASH only accounts for 0.42% of the total budget of the National Institute of Diabetes and Digestive Kidney Diseases (NIDDK), the unit within the National Institutes of Health that houses a majority of liver health research. #NASHday
Sample Blog Post
June 12 - International NASH Day
Today is International NASH Day! [ORGANIZATION] is proud to join the Global Liver Institute (GLI) in raising awareness of this important health issue.
Non-alcoholic steatohepatitis, or NASH, has been called an epidemic, a ticking time bomb, and a silent tsunami. It is the progressive form of non-alcoholic fatty liver disease (NAFLD), and affects more than 115 million people worldwide. An estimated 357 million people will be affected by 2030.
Because NASH symptoms are not overt, NASH is often underdiagnosed and underreported. NAFLD and NASH are major risk factors for other health conditions: more than 70% of patients are obese, up to 75% have type 2 diabetes, and anywhere from 20-80% have hyperlipidemia. Unchecked, NASH may lead to cirrhosis, liver cancer, and liver transplant.
Despite its prevalence and serious health consequences, NASH is relatively unknown. In a recent survey, only 6% of at-risk individuals had ever heard of NASH.
Against this backdrop, the first International NASH Day (IND) was launched on June 12, 2018, with the goal of raising awareness about NASH and the actions people can take to prevent the disease. Now under the Global Liver Institute’s leadership, International NASH Day is set to build off last year’s successes.
“We urge everyone to spread the word about NASH and its effects,” Donna Cryer, GLI’s President and Founder said. “Our goal is to shine light on this silent epidemic.”
[QUOTE FROM ORGANIZATION’S LEADERSHIP]
For more information, visit globalliver.org/IND